The
Cure
Parkinson's
Trust

2018 ANNUAL REVIEW

Cure^3

Private View 25 October 2018
Exhibition: 26-28 October 2018

Bonhams
101 New Bond Street
London W1S 1SR

Save the Date



Following a hugely successful event in 2017, the Cure^3 exhibition returns in October 2018.

In March 2017, Cure^3 launched with 53 artists of international standing all creating an art work using a bespoke Perspex box 20cm^3 with the box serving as a space to frame, support or contain each work, allowing for multiple approaches and interpretations. The artworks were sold and all the money raised went to CPT to help find a cure for Parkinson's.

Curated by Susie Allen & Laura Culpan, Artwise
In partnership with Bonhams, one of the world's oldest and most prestigious auction houses

> *"The Cure Parkinson's Trust (CPT) is all about the cure. Tom Isaacs' inspiration and enthusiasm lives on in the charity and our continuing efforts to slow, stop or reverse Parkinson's. This vision is championed by our entire team, and our resolve to achieve it has been strengthened by his passing. We have a job to do."*

Will Cook, CEO The Cure Parkinson's Trust

Tom Isaacs

Tom and Lyndsey Isaacs

Innovating... *for a cure*

Charlie Ralph, Chair of the Board of Trustees and Will Cook, Chief Executive Officer.

The Cure Parkinson's Trust is a determined and focus-ed charity. We were honoured to take up our roles during 2017, albeit in a year of great sadness as we reacted to the tragic death of Tom Isaacs, CPT Co-founder and President. The team has shown extraordinary resilience: despite the immense challenge, the charity concluded the most successful fundraising year ever, enabling the Trust to invest nearly £1.5 million in new external research towards finding a cure for Parkinson's.

CPT prides itself in exceptional standards in evaluation and selection of the research we fund, and measuring the impact of that research, as well as the strength of our internal governance and management. To support this, the Trustees have recast the executive leadership and appointed Will Cook as CEO supported by Helen Matthews as Deputy CEO. Both Will and Helen share an energy and commitment demonstrated over several years as Trustee and COO respectively, alongside our inspirational Director of Research & Development, Dr Richard Wyse, and supported by the rest of the talented and committed team. The Trustees would also like to thank our previous Chair, Ken Mulvany, for his leadership and support over the last five years.

This is an exciting time to be involved in Parkinson's research. Results are coming in from the recent clinical trials funded or supported by the charity, and further trials are underway. The Trustees are hugely grateful for the rigour and commitment shown by the leading scientists and clinicians giving their time to our two advisory committees: the Linked Clinical Trials (LCT) Committee which reviews and recommends the most promising drug candidates for trial, and our Research Committee which then evaluates proposals for LCT drug trials or pre-clinical research. The Trustees gain huge confidence from the recommendations of these leading experts when making funding decisions.

2017 saw the charity invest more heavily than ever into our charitable activities, but - as we raise further funding - there is much more we can do. Our promising LCT programme alone needs significant support if it is to reach its full potential.

We continue to build upon our strong international research and co-funding partnerships, particularly with the Van Andel Research Institute (VARI) and The Michael J Fox Foundation in the US, as well as the University of Queensland, the Garvan Institute and Shake It Up Australia. Further LCT trials are underway or imminent in France and Australia.

Another important aspect of our work remains ensuring that people with Parkinson's (PwP's) inform our research-based decisions. We engage with patient advocates regularly, and patient engagement drives www.parkinsonsmovement.com that is designed to dispel hype from hope, encourage advocacy and support research.

But CPT is all about the cure. Tom Isaacs' inspiration and enthusiasm lives on in the charity and our continuing efforts to slow, stop or reverse Parkinson's. This vision is championed by our entire team, and our resolve to achieve it has been strengthened by his passing. We have a job to do.

Charlie Ralph

Will Cook

Helen Matthews

Charlie Ralph, Will Cook and Helen Matthews took up new roles at CPT in 2017

Breakthroughs... *for a cure*

It was another busy year for the Research Committee. More than 30 projects were evaluated of which 11 projects were funded. Projects that particularly resonate with the Research Committee are those which are innovative and have the potential to help us identify the right treatments to move into disease modifying clinical trials either because they are identifying a new mechanism, or a new drug, or add understanding on how a drug works.

"The aim of CPT remains unchanged: to find a cure for Parkinson's disease (PD). To this end, the Research Committee carefully scrutinises all submitted research applications for funding, assessing them for their potential to slow or arrest progression of the disease, or to promote regeneration in order to restore normal function. These are ambitious targets, but they define CPT's reason for existence and its mission.

The Research Committee considers both basic neuroscience projects that seek to understand better the cause and pathology of Parkinson's disease, but places particular emphasis on research that seeks to translate promising and exciting basic scientific discoveries into clinical practice. This is a challenging task, and the membership of the Research Committee is continuously reviewed to ensure that it is equal to the task.

The international Linked Clinical Trials (LCT) initiative, conceived and facilitated by CPT, has already promoted clinical trials of major importance, and is now being recognised as a model applicable to other diseases in clinical translational neuroscience research."

Dr John Scadding
Chair of the Research Committee

Identifying disease modifying treatments using induced neurons

In November, CPT's Research Committee recommended funding for a project from Professor Roger Barker's lab to identify drugs that affect Parkinson's using patient-based "induced neuronal" (iNs) cells with a view to determining which drugs are most likely to slow or stop disease progression.

Samples of skin cells will be taken from patients with specific types of Parkinson's and turned into nerve cells, by using a virus that contains a variety of "reprogramming" factors. These cells will therefore come from patients with Parkinson's and importantly be turned into nerve cells of the type affected by the disease in the patient's brain.

We will study these nerve cells to see what processes are not working correctly. The nerve cells will then be treated with a variety of drugs (particularly LCT candidate drugs), to see if they can correct the problems that we see. Any drug that does this will be a good choice to trial in patients to see if it is able to slow the disease.

> *"The exciting aspect of this work is the ability to make brain cells from patient skin cells, which retain age and hopefully the pathology underlying their form of Parkinson's. This should in theory then allow us to screen drugs for effects in those cells, which ultimately could lead to personalised treatments for patients with this condition."*

Professor Roger Barker
John Van Geest Centre for Brain Repair, Cambridge

Pictured above: Professor Roger Barker at CPT's Spring Research Update Meeting, 11 April 2018

More about diabetes

Researchers at the Van Andel Research Institute in Michigan are testing the effects of two drugs developed for diabetes, both individually and in combination, in two Parkinson's models that mimic different features of PD (e.g. protein clumping, nerve cell death and inflammation). One of these drugs (exenatide) has already shown clinical promise as a treatment that potentially modifies disease worsening in Parkinson's. The other drug (MSDC-0160) has been tested extensively and generated positive results in several cell culture and other models of PD. The planned experiments will have immediate clinical relevance as they will guide whether it is worth testing both compounds in combination in clinical trials, which would be ground-breaking.

The team predicts that both exenatide and MSDC-0160 will protect against the Parkinson-like neuropathology in both models. They also predict that the combination of the two drugs will have even more powerful disease modifying effect than each drug might exhibit on its own.

"As we learn more about Parkinson's, it is becoming increasingly clear that it is a complex, multisystem disorder with significant variation from person to person. Therefore, combining multiple therapeutic strategies might be the best way to treat the disease's underlying, diverse causes and slow progression of the disease. I believe this approach merits significant exploration as it could truly lead to better quality of life for patients, lasting many years. Of course, our dream is that one day we can prevent the disease altogether."

Professor Patrik Brundin
Center for Neurodegenerative Science at Van Andel Research Institute

Exenatide: Who responds? How can we tell?

In June the Research Committee recommended a project to carry out further analysis on the exenatide trial dataset. The project has explored not only the non-motor data that was collected in the trial to understand any change in individual and group data, which might inform any larger trials to come, but also has specifically questioned the data to understand who responds. Some of this may be answered by understanding genetics, and analyzing exosomes.

"In collaboration with a team at the National Institute of Health (NIH) we have found that exenatide appears to engage and normalise brain insulin signalling pathways and that these changes contributed to the beneficial effects seen in the clinical trial. Ongoing analysis of the trial data has identified a number of new research questions which we hope to answer in a more extensive clinical trial. "

Dr Dilan Athauda
UCL Institute of Neurology

"I joined the Research Committee in 2017 as a layman with a non-medical professional background to be a voice of people with Parkinson's. It has been an honour to participate in the Committee's work as a discerning gatekeeper for research projects. We are at an unprecedented moment where with thought, resource and persistence we will imminently advance CPT's objective - to find a cure."

Anthony Temple QC
CPT Research Committee member 2017-current

Applying for funding

CPT funds and facilitates laboratory or clinical research projects with the potential to advance knowledge that might lead to a cure for Parkinson's disease. Projects should be disease modifying (slow, stop, reverse) and translate into clinic (Phase 2 trial) within five years.

AMRC Membership

CPT is a member of the Association of Medical Research Charities (AMRC) which is recognised as a quality mark demonstrating that vigorous peer review processes are in place so that only the highest quality of research is supported.

For more information or to apply for funding, please go to
www.cureparkinsons.org.uk/applyfunding

Linked Clinical Trials... *for a cure*

In devising the Linked Clinical Trials initiative (LCT), The Cure Parkinson's Trust has established a systematic and successful way to evaluate a large number of treatments all with the potential to alter the progression of Parkinson's. Dr Richard Wyse, CPT's Director of Research & Development, explains:

"It is our dream that our innovative approaches will eventually allow people with Parkinson's to enjoy completely normal lives."

For the past decade CPT has been a major global driving force behind several ground-breaking initiatives in the search for a cure for Parkinson's (PD). We are now an organisation that has already made astonishing worldwide advances towards our bold aim to slow, stop and reverse the progression of Parkinson's. It is our dream that our innovative approaches will eventually allow people with Parkinson's to enjoy completely normal lives. We explore and develop in detail many of the breakthroughs involving regenerative and conventional (drug) medicine approaches that are of direct relevance to the current and future treatment of people living with Parkinson's. We achieve this by working closely with a large number of those excellent scientists and clinicians from around the world who are currently making these important discoveries in their laboratories and their Parkinson's clinics.


The annual Linked Clinical Trials meeting at the Van Andel Research Institute (VARI), Grand Rapids, Michigan, 2017

We are passionate about facilitating and ensuring that these cutting-edge new developments enter clinical trials in patients as rapidly as possible. In the Linked Clinical Trials programme which CPT launched in 2012, we have brought together annually 15 of the world's Parkinson's experts to form a committee to select the most promising new therapeutics for us to take into long term disease-modifying clinical trials. Over this time CPT has reviewed the therapeutic relevance to patients of around 2,000 drugs that are already used in many other disease areas (and therefore already known to be relatively safe medications). We have particularly focused on the added potential of each of these drugs to slow neurodegeneration in people with Parkinson's. From the list of around 2,000 drugs, we have selected approximately 150 of the most promising candidates for the committee of world renowned experts to review and discuss in regular face-to-face meetings. Through knowledgeable and rigorous debate, this committee selects which of these potential treatments should be recommended for long term clinical trials. They determine, drug by drug, which is most likely to slow, stop and/or reverse progression of Parkinson's. By this stringent process, so far our international expert committee has selected 38 of our 150 therapeutic drug candidates to enter our long term clinical trial programme.

"This massive clinical undertaking involving so many drugs repurposed from other therapeutic areas is unique not only in neurology, but is larger than any drug development programme, whether academic or commercial, in any other disease."

Currently, under this unique initiative, ongoing CPT clinical trials already involve 80 leading neurology hospitals in the UK, France, Germany, USA and Australia, with several new trials having been launched over the past year or two, notably the Nilotinib trial in 25 hospitals in the USA, and the Lixisenatide trial in 21 hospitals in France. By the end of 2018 we anticipate we will have at least 14 of the 38 trials either underway or finished, and hope to launch another eight clinical trials in 2019. This massive clinical undertaking involving so many drugs repurposed from other therapeutic areas is unique not only in neurology, but is larger than any drug development programme, whether academic or commercial, in any other disease.

> *"CPT is changing the traditional ways in which we have long been treating PD"*

The results of the first LCT drug trial were published in *The Lancet* last August. It demonstrated that most of the patients on active drug treatment (exenatide/Bydureon) were protected from disease progression for the entire one-year duration of the study, making this the first time this has ever been achieved since Parkinson's was first described over 200 years ago. CPT also published a commentary on this trial in the medical literature to describe its outstanding importance to the field. We are currently planning the larger follow-up trial of this drug that is a necessary statutory requirement before this treatment can be approved by the drug regulators for widespread use in Parkinson's patients.

It is my delight to be working within such a vibrant organisation. CPT is changing the traditional ways in which we have long been treating PD (and we all know that currently available symptomatic treatments do nothing to stop patients getting progressively worse over time). It is also my delight to be working with some of the finest PD experts from around the world, with all of us absolutely determined to deliver our shared objective of consigning this debilitating disease to the medical history books.

Read more about exenatide on pages 8 and 9 and at:
www.cureparkinsons.org.uk/news/bydureonresults
www.content.iospress.com/articles/journal-of-parkinsons-disease/jpd171192

Calling all Trusts & Foundations

At The Cure Parkinson's Trust, we work in partnership with trusts and other funding bodies around the world to support clinical trials within the Linked Clinical Trials programme and cutting edge research into a cure for Parkinson's.

The John Black Charitable Foundation has generously funded a Linked Clinical Trial investigating an anti-mucolytic drug called Ambroxol and the results of this study should be available later in 2018.

> *"The John Black Charitable Foundation is delighted to be working with The Cure Parkinson's Trust and the Van Andel Research Institute to support Professor Schapira's research into Ambroxol. We were excited by the project; we were impressed by the detailed investigation made by CPT prior to our becoming involved and with the opportunity to co-sponsor beside a world class institution such as Van Andel. This study will reach its conclusion later this year and we are looking forward to seeing the results to understand whether Ambroxol could be developed through a larger clinical trial as a potentially disease modifying treatment for Parkinson's."*

David Taglight
The John Black Charitable Foundation

If you are a trust or organisation and would like to find out more about supporting our LCT programme, please contact **maisie@cureparkinsons.org.uk** or call 020 7487 3892

Prof. Patrik Brundin and Dr Richard Wyse lead the 2017 LCT committee meeting

Keep up-to-date with research

CPT hosts at least two research meetings a year for people affected by Parkinson's. To view talks from our meeting in April 2018, please visit, **www.cureparkinsons.org.uk/spring-research-update-meeting**

CPT's Dr Richard Wyse presents the latest LCT developments

Details of our LCT programme and other clinical trials we are centrally involved with are available at **www.cureparkinsons.org.uk/clinical-trials**

Making medical history... *for a cure*

In August 2017, *The Lancet* published the results of the second clinical trial of exenatide. These ground-breaking results showed an improvement in people who took the drug over 48 weeks compared to those taking placebo – suggesting that exenatide could be slowing down or stopping the progression of Parkinson's.

CPT supporting work with exenatide since 2010:

CPT has been involved in the development of exenatide for Parkinson's since it funded the first open-label trial at University College London (UCL) in 2010. The charity not only funded the study in its entirety but also supported recruitment to the trial, and dissemination of the results of this work. In the more recent trial using the weekly version of the drug, Bydureon, the charity has supported the recruitment of participants, sourcing individuals with Parkinson's for the trial steering committee. It has also worked with the study team to share information with the participants and the wider public.

> *"This was a watershed moment for Parkinson's research – confirmation that a clinically available drug could potentially be re-purposed for this condition. And while the positive effects were limited to just the motor features, it still represented the moment that the mind-set shifted from 'if we find a cure' to 'when we find a cure'. It is a very exciting time to be involved in Parkinson's research."*

Dr Simon Stott
Parkinson's researcher, University of Cambridge
www.scienceofparkinsons.com

Next steps

> *"This is the strongest evidence we have so far that a drug could do more than provide symptom relief for Parkinson's."*

Professor Tom Foltynie
Research lead for the trial at UCL

It is hoped that a larger phase 3 trial led by Professor Tom Foltynie at UCL is now proposed, which will be necessary to move exenatide towards the clinic. This proposed trial is twice as long as the previous study, involving 200 people with mid-stage disease in a placebo controlled trial.

If the benefit that has been visible in the previous two studies is repeated and if increased benefit is seen from the longer exposure to the drug, there will be compelling evidence to make this treatment available to the 10 million people affected by the condition worldwide.

Ongoing involvement and commitment:

In May 2017, CPT hosted a meeting for researchers working in this area to identify areas of collaboration, details of which can be found on our website.

In June 2017, with the support of a partner charitable foundation, CPT approved £45,000 of funding to Professor Foltynie and his team to carry out further investigations into the trial data, particularly to understand who responded to the treatment best and why. This vital work has helped (and will continue to help) shape the recruitment strategy of this proposed new trial.

In August the charity hosted a workshop for people with Parkinson's to analyse the trial design, duration and assessments. As a direct result of this workshop the duration of the study was reduced and guidance has been created around carrying out assessments "off medication."

For more information about the exenatide results and our wider research into type 2 diabetes drugs please visit
www.cureparkinsons.org.uk/glp1meeting

Pictured above: A group of volunteers with experience of clinical trials joined members of the CPT research team to help shape the next stage of the Bydureon study

"The exenatide PD trial was only 60 strong. I wanted to contribute positively to the future, to help close a blind alley or define future treatments. Taking part in research is a hugely rewarding experience but also for me was the responsible thing to do.

It was very instructive to be on the trial - my experiences have helped shape the next phase of this research through a workshop that evaluated the trial design, its length and the outcomes to be considered."

Tim Butterfield
Trial participant
(Pictured below with wife Carol and daughter Rachel)

We need your help

Since its inception in 2012, the Linked Clinical Trials programme has gone from strength to strength. CPT has been a catalyst in ensuring trials of potentially disease modifying drugs get underway. We are leaving no stone unturned to identify treatments to slow, stop and even reverse Parkinson's and believe that by identifying existing drugs that show the biochemical potential to change or modify Parkinson's is the quickest way to fast-track treatments for 10 million people with the condition worldwide.

Each trial can cost in the region of £2 million or more. Although we work in partnership with other funders, we urgently need funds to ensure that the right trials get underway quickly. This year CPT will be involved in helping develop a number of phase two and phase three trials of potentially disease-modifying drugs, which means we are moving closer to having tangible treatments that **slow**, **stop** or **reverse** the disease. We need your help now more than ever.

Please pledge your support. By using the envelope enclosed, help us make history in developing what might be the first disease modifying treatments for Parkinson's.

The clinical trials process

Clinical trials are necessary to see how effective and safe certain treatments, interventions or diagnostic tests are in humans. For a new treatment to get from the idea stage to the clinic it usually takes 10–15 years.

Phases 1 and 2

Phase 1 tests a new drug in a small group of healthy volunteers to evaluate safety, determine a safe dosage range, and identify side effects.

Phase 2 trials are the first occasion in which a new drug is given to a larger group of people with the condition.

Phases 3 and 4

The data from phase 3 trials is used to confirm the safety and effectiveness of a new drug. This also allows the drug to be compared to other existing treatments.

Phase 4 trials are usually conducted after a drug has been marketed and are mainly used to monitor safety and to define optimal usage.

CPT's LCT programme aims to significantly reduce the time it takes to bring drugs to clinic by using treatments already approved for other conditions.

Get involved... *for a cure*

Created and run by people living with Parkinson's (PwP's), Parkinson's Movement (PM) has moved into a new era, with an emphasis on advocacy and patient involvement. PM was the brainchild of three people with Parkinson's - Dr Jon Stamford, Sara Riggare and the late Tom Isaacs. As PM evolves, the mantle has been taken up by advocates all over the world, led by Eros Bresolin, Gaynor Edwards, David Sangster and Dr Jon Stamford. The new website went live in early February.

The redeveloped site, supported by funding from The October Club, now focuses on three key areas:

Understanding research:

This area features research articles that make the media headlines. Articles are presented in a balanced way, translating the science into plain English, dispelling the hype and yet providing hope.

Participating in research:

This area showcases the best in Parkinson's advocacy, highlighting where great advocacy makes a difference to research projects. The advocate wall highlights talent and experience of incredible advocates around the world who are involved in research and creates a way for researchers to reach the advocates they need for their projects.

Contributing to research:

By sharing information about symptoms through Fox Insight, Michael J Fox's surveying platform.

"It is hugely important that we retain the original spirit of PM. Tom's vision of patient involvement guides everything we do at CPT and PM," says Helen Matthews, Deputy CEO, who worked alongside Tom for 15 years until his untimely death in May 2017. *"PM is part of Tom's legacy. At the heart of the site is the advocacy wall - people with Parkinson's all working towards a greater understanding of this complex condition,"* she continues. *"Whether research volunteers, public speakers, lifestyle writers or those willing to be interviewed about their PD - all are contributing."*

David Sangster

"We must act collectively, as a community, to keep talking about Parkinson's. We must all continue retweeting, right-clicking, sharing, copying and pasting and blogging about it, so that we can keep the positives out there for the benefit of PwP's and to also raise awareness and re-educate the public perception of PD."

David Sangster

Dr Jon Stamford

"Over the last decade or so, CPT has - much like the World Parkinson Congress - made huge strides in getting those with Parkinson's to realise they have an invaluable role to play. There are some hugely knowledgeable people within the PD community now, there are also some excellent scientists out there working with them. This new site will hopefully bring these two groups closer together. After all, we all want the same result - better treatment and a cure."

Dr Jon Stamford

Co-founder of the original PM, Jon will also be writing for the new site - with his unusual perspective as both a person with Parkinson's and someone who worked in Parkinson's research for many years pre-diagnosis.

Eros Bresolin

"It has been an honour to help bring Tom's vision of Parkinson's Movement alive by creating an online presence that encourages PwP's to step out from their shell, while focussing on research and talking about symptoms."

Eros Bresolin

Gaynor Edwards

"The essential difference that this new version offers is greater accessibility and collaboration with researchers. If the end result is that researchers connect in the same way as patient advocates have done, we'll be cooking on gas."

Gaynor Edwards

Nominate for The Tom Isaacs Award

Nominations are now open for The Tom Isaacs Award to recognise the work of a researcher/professional who has demonstrated significant impact on the lives of people living with Parkinson's and has involved people with Parkinson's in a participatory way in their work.

The award was created and is co-awarded by The Cure Parkinson's Trust and The Van Andel Research Institute and is presented at the annual Grand Challenges in Parkinson's and Rallying to the Challenge meeting. In 2018 this is taking place on 26-27 September at VARI, Grand Rapids, Michigan.

Tom Isaacs co-founded The Cure Parkinson's Trust and Parkinson's Movement. Diagnosed at the age of 26, Tom was one of the best known Parkinson's advocates in the world. He believed that a cure for Parkinson's can and will be found, but greater value will be gained from working with people with Parkinson's in this quest.

How to Nominate

Nominations opened on 11th April 2018 and close on 31st August 2018. Any person can nominate, including patients and colleagues, and nominations will be accepted from anywhere in the world. Nominations will be evaluated by a panel selected by VARI and CPT comprising researchers, people living with Parkinson's and Lyndsey Isaacs, Tom's wife.

To submit a nomination, please visit www.cureparkinsons.org.uk/ti-award-2018

2017 winner Professor Tom Foltynie receives his award from Lyndsey Isaacs

"Professor Foltynie managed to convert Tom Isaacs' dream into reality. By conducting two clinical trials with the anti-diabetic agent exenatide in Parkinson's - both yielding exciting and promising results - Professor Foltynie showed that the idea of drug repositioning is viable. It is really quite a remarkable achievement and could end up being a milestone in the history of Parkinson's."

Professor Patrik Brundin
Associate Director of Research at VARI

"During my time working in the Parkinson's field, I have come to realise there is a patent lack of communication between scientists, clinicians, people living with Parkinson's, industry and charities. There is no doubt in my mind that if we all worked together, it would unlock the gates to a wealth of new thinking, new ideas and, most importantly, pave the way to a spate of breakthrough treatments."

Tom Isaacs
Former President, The Cure Parkinson's Trust

2017 *for a cure*

2017 was a year of great achievements but also great sadness. In May, our Co-founder and former President Tom Isaacs sadly passed away. Tom made an enormous contribution to changing the face of Parkinson's research and we dedicate our memories of 2017 to him.

March 2017

In early Spring CPT partnered with The British & Irish Lions to raise funds for research. As part of this collaboration Dr Tilo Kunath hosted Lions' coach Warren Gatland and Scottish rugby legend Gavin Hastings for a fascinating day at his research laboratory at the University of Edinburgh where CPT funds some of Dr Kunath's groundbreaking stem cell research. Pictured above left to right: Warren Gatland, Tom Isaacs, Dr Tilo Kunath and Gavin Hastings.

March 2017

CPT partnered with Bonhams and Artwise to put on Cure^3. Over 50 artists including Damien Hirst and Peter Blake exhibited and sold works to raise funds for CPT. Look out for information on this year's Cure^3 exhibition.

March 2017

We were thrilled to have an opportunity to appeal directly to viewers on the BBC for funds for Parkinson's research. CPT's BBC Lifeline appeal, which featured advocates Rachel Gibson and David Sangster, raised over £67,000. Pictured above: Professor Tom Foltynie and Rachel Gibson.

May 2017

In May we were honoured and delighted to be one of the beneficiaries of Mike Tindall's celebrity golf day which took place at The Belfry Golf Club. Pictured above (left to right): Lyndsey and Tom Isaacs and Mike and Zara Tindall.

May 2017

Our annual Bluebell picnic was held once again in the beautiful grounds of Hedsor Park. As always, it was a wonderful day of traditional games and family entertainment and we are incredibly grateful to Janey and Alexander Shephard who make this delightful venue available to us each year.

May 2017

The annual Gulls' Eggs Luncheon was a huge success with over 600 guests from the wealth management sector coming together for a networking lunch at Merchant Taylors' Hall to raise funds for CPT.

September 2017

In September we celebrated the life and achievements of Tom Isaacs. Tom was an inspiration to all those who met him and pioneered research into curative treatments for Parkinson's.

November 2017

In November we hosted a research update meeting for people affected by Parkinson's at the offices of Deloitte in London. Among those speaking about the latest research developments were Dr Simon Stott and Dr Dilan Athauda.

September 2017

The sixth Linked Clinical Trials (LCT) conference which aims to identify possible new ways to slow, stop and reverse Parkinson's was hosted by the Van Andel Research Institute (VARI). 21 different treatment options were discussed, each with the potential to change the underlying disease processes.

October 2017

The renamed 'Tom Isaacs Charity Golf Day' at Denham Golf Club saw a record number of players taking part. 78 people came together to remember Tom at one of CPT's longest-running events and one which Tom always thoroughly enjoyed.

November 2017

Over 250 guests and supporters were kept amused and entertained by a crack team of comedians including Tim Vine, Alan Davies, Tony Hawks and Arthur Smith who came together in an evening of fun and laughter to help raise funds for CPT at the Comedy Quiz Night.

Raising the funds... *for a cure*

Tim Daber (right) keen supporter of The Cure Parkinson's Trust (CPT) talks about his experience of fundraising in support of our pioneering Parkinson's research and why you should get involved if you're thinking of fundraising too.

"The sense of achievement you will feel when you stage a successful event, complete a challenge or hit your fundraising target is unbelievable."

I was diagnosed with Parkinson's in 2016 and, like many others, was told that it was an incurable disease. I had known for some time something was seriously wrong: my right arm was just hanging limply as I walked rather than swinging in time with my stride and my handwriting was becoming shaky - in my mind I imagined the worst. Fortunately for me it was an early diagnosis and my symptoms were quite mild.

What was to become a defining moment happened on 10th April 2017 during Parkinson's Awareness Week when I heard a Professor of Neurology interviewed on national radio. The Professor said that in his opinion, a cure for Parkinson's was possible within the lifetime of some people living with the disease if only more funding was invested in research.

"I was stunned as it had never for a moment occurred to me that a cure hadn't been found due to a lack of funding. I knew immediately that I had to do something about it."

By that weekend I had come up with the plan to walk 60 miles around the scenic North Norfolk coast path from Sea Palling to Hunstanton in August 2018, naming my challenge the 60/60 walk with a fundraising target of £100,000. The idea of walking 60 miles to mark my 60th birthday seemed a fitting way to help reach my fundraising goal. I ran the idea past my closest family and friends who thought I should go for it and were more than willing to help me. I wanted to support CPT in my fundraising mission as they are the only organisation in the UK solely dedicated to finding a cure for Parkinson's which for me was the ultimate objective. From my first conversation with CPT's Deputy CEO, Helen Matthews, I never doubted I had made the right choice such was her knowledge and enthusiasm.

Now over halfway through my fundraising challenge, I have already encountered some amazing generosity. Hunstanton Tennis Week, Britain's biggest open tournament, agreed to adopt my walk for CPT as their supported charitable cause for the year. I held an official fundraising launch party in February at the wonderful Tap and Kitchen in Oundle, Northamptonshire owned by friends of mine who kindly offered me the use of their premises to host the event. Local businesses and individuals donated some fantastic and generous prizes for the auction and raffle and the evening raised substantial funds, exceeding my expectations.

My friend Keith provided over £15,000 in match funding through his company Axtec based in Runcorn which was truly astonishing.

I have many more exciting events planned over the next few months including a tennis club quiz night in Oundle, a wine tasting evening and a children's sponsored walk. I have also started to train for my 60/60 Norfolk Coast walk in August, and have already recruited 25 family and friends to take part with me all of whom are seeking their own sponsorship.

"My real message to anyone thinking of fundraising for CPT is to go for it!"

Donations all build up and if only 10 people reading this each raise £250 that is £2,500 that CPT can then invest in ground-breaking Parkinson's research. If you have even bigger fundraising plans - fantastic! People are amazingly generous when it comes to raising money for such an incredible cause and the sense of achievement you will feel when you stage a successful event, complete a challenge or hit your fundraising target is unbelievable.

If you are thinking about fundraising for CPT and would like to find out about how we can support you, please contact George at **george@cureparkinsons.org.uk**

Donate... *for a cure*

Neurological disorders are now the leading cause of disability in the world and the fastest growing is Parkinson's disease. Urgent investment in research is needed to **slow**, **stop** and **reverse** the condition and there are a number of ways you can help us to do this.

Making a payroll donation

Payroll giving is an easy, tax-efficient way to make a regular donation. By committing to Payroll Giving, you can help to provide a regular and reliable income stream that allows us to budget for future research projects.

Payroll donations are taken out before tax, so a £10 donation would only cost you £8 if you are a standard rate tax payer or £6 if you are a higher rate tax payer. Payroll giving is simple and easy to set up – there are no bank details required and you can change or stop your donation at any time.

"Payroll giving really works for us as we can make decisions at the start of the year about how much of our earnings we want to go to charity, set up all of those charities in one place and the money is deducted out of our salary before we even see it - with the added bonus that our tax is all correctly adjusted for it too."

CPT supporters Alison and Grant

Making a regular donation

Every donation to The Cure Parkinson's Trust helps us move closer to finding a cure for Parkinson's; we are so grateful to all our donors at whatever level people can give. Regular donations from as little as £5 a month are significant as they turn into a large commitment over time, and provides us with the knowledge that there is ongoing funding available.

"We have seen within our own family the consequences of a diagnosis and living with Parkinson's. We are delighted to be able to support the work of The Cure Parkinson's Trust with an annual gift. Our donations help CPT support the brightest and most inspiring researchers, offering hope to everyone who knows what it is like to live with or witness a family member living with Parkinson's first hand."

CPT supporters Victoria and Michael

To support our Linked Clinical Trials programme, in 2018 we will be launching a philanthropic regular giving club for those who would like to donate £5,000 or more per year for five years. To find out more about joining the Cure Collective please contact Theresa **theresa@cureparkinsons.org.uk** or call 020 7487 3892.

Payroll Donation

To find out how to set up your own payroll donation please visit, **www.cureparkinsons.org.uk/payroll-giving** Alternatively please contact Ella at **ella@cureparkinsons.org.uk** or call 020 7487 3892 for further information.

Regular Donation

If you would like to find out more about how to set up a regular donation please visit **www.cureparkinsons.org.uk/giveregularly** or contact Sarah at **sarah@cureparkinsons.org.uk**

Major Gifts

If you are considering making a donation of £5,000 or more please contact Theresa at **theresa@cureparkinsons.org.uk** or call 020 7487 3892 for further information.

There are so many ways that you can give. To find out more contact a member of the fundraising team at **cptinfo@cureparkinsons.org.uk** or call 0207 487 3892

Fundraising... *for a cure*

Every year our individual fundraisers inspire us as they take on some truly spectacular fundraising and challenge events in support of The Cure Parkinson's Trust (CPT). We'd like to take this opportunity to thank each and everyone of our fundraisers for their incredible support and fundraising efforts. Here we share and celebrate some of their wonderful fundraising stories from 2017 with you.

Izzy King

"My grandad has Parkinson's and it's so sad to see him struggling everyday. I wanted to raise money to find a cure, to help my grandad and other people. Last June I did a five mile sponsored walk to fundraise for CPT, and won the Ward & Partners 'Young Fundraiser of the Year' Award. This year I'm organising a Charity Dog Show and I'm hoping to raise lots more."

Izzy King (above)

Eric Johnstone

"Last April I held a fundraising dinner for 80 people at Seckford Golf Club in Suffolk. Judging by the number of people who have since told me they wished they had known about it I could have staged it over three nights! We had the usual raffle, an auction, wonderful food plus a magician and a comedian who each gave us their time for free. I couldn't have done it without the help and brilliant organisational skills of Simon Jay, Director of Golf at Seckford. Together we raised a fantastic amount for The Cure Parkinson's Trust."

Eric Johnstone (above left with Simon Jay)

Olivia Hardy



"Few moments are as great as watching your 72-year-old father cross the finish line of the Virgin Money London Marathon, apart from doing it hand-in-hand in CPT branded vests. We embarked on our fundraising mission in October 2016, launching months of bucket collecting outside Aldi, a wine tasting evening at our local church hall, an eight-hour 'spinathon' at our gym, and a black tie Ceilidh at the London Scottish Regiment's Drill Hall. Thanks to some incredibly generous friends, family and utter strangers, we watched our target creep up. We thought how great if we could raise a little bit more, and then a little bit more than that. A little bit more then became a whole lot more than we ever imagined. To everyone who gave us our little bit more, it means more than you know and we hope that a little can go a long way to finding a cure for Parkinson's."

Olivia Hardy (above right with father James)

Kerry Ainge



"On New Year's Eve 2016 after a few too many glasses of bubbles, myself and three friends had the amazing idea to take on the Vitality London 10,000 to fundraise for CPT. We were due to commence training that January, but unsurprisingly didn't actually begin until March. The day itself was fantastic, albeit a tiring one. On a personal level it meant a lot to be able to complete the run having been diagnosed with Parkinson's just two years earlier; not what you expect when you have a one year old daughter. CPT is focused on doing just what it says on the tin: finding a cure for Parkinson's. This cannot come soon enough for me, I want to be able to continue to enjoy being with my daughter, partner, family and friends, with the comfort of knowing that my Parkinson's will not progress or better still, that I along with thousands of others will be cured."

Kerry Ainge (above third from left with team mates)

Louisa Platt

"Last December I held a Christmas Fair in support of The Cure Parkinson's Trust. My father had Parkinson's for many years and sadly passed away last April so it was easy to decide where I wanted our fundraising to go. All the stall holders who took part donated 10% of their sales and we sold an incredible 967 raffle tickets, all together raising a fantastic amount for Parkinson's research that exceeded my expectations. I was very moved by the amount of people who came and supported the fair and by how many of those have been affected in some way by this disease."

Louisa Platt (above)

Fundraiser News

To find out what more of our fundraisers have been up to in support of CPT, please visit our 'Fundraiser News' section of the website at **www.cureparkinsons.org.uk**

Fundraising Tips

For lots of useful tips and tricks to help you with your fundraising, please visit our 'Fundraising Tips' section at **www.cureparkinsons.org.uk**

Keep In Touch

Share your fundraising efforts with us on social media, we'd love to hear from you!

Twitter: @cureparkinsonsT

Facebook: @cureparkinsons

Instagram: @cureparkinsonstrust

If you would like to take on a challenge in support of CPT, please contact George at **george@cureparkinsons.org.uk** or call 020 7487 3892

Excelling... *for a cure*

The Alex Flynn Fundraiser of the Year Award recognises the individual who has gone above and beyond to raise funds and/or awareness for Parkinson's. This year's recipient of the award is Alison Anderson from Cheltenham, Gloucestershire whose extraordinary fundraising efforts, which included cycling from Vietnam to Cambodia, have raised over £42,000 for The Cure Parkinson's Trust and provided inspiration and hope to people with Parkinson's.

The Cyclopaths

Alison Anderson was diagnosed with Parkinson's almost three years ago, at the age of 46. Inspired by a meeting with the late Tom Isaacs, President and Co-founder of The Cure Parkinson's Trust, she decided to embark upon an ambitious cycle challenge which saw Alison pedal over 500km from Vietnam to Cambodia, raising funds for CPT. *"Tom's positivity, humour and all that he had achieved made me realise that with the right attitude there is no limit to what we can do,"* she recalls. Undeterred by her condition, Alison decided to take on a huge physical challenge in support of CPT.

Alison was joined by a team of fifteen others, mostly non-cyclists, to embark upon one of the greatest (and most challenging) cycle routes available. The group became known as 'The Cyclopaths' and they dedicated themselves tirelessly to ten months of training in preparation for the route which would take them from Ho Chi Minh City in Vietnam to Ankor Wat in Cambodia.

Cycling up to 90 kilometres per day in the unrelenting humidity of Southeast Asia, through dirt track roads and untrodden paths is no mean feat for even the most seasoned of cyclists. Yet, The Cyclopaths completed the challenge with unyielding enthusiasm. *"I loved every single minute of it. We saw the real Cambodia and Vietnam, far away from the tourist routes. It was physically demanding and time consuming but we had so much fun. We became a fantastic team and we all shared and gained something from this wonderful experience."* said Alison

In addition to this incredible physical challenge, the group spent months raising funds through a variety of other means, from coffee mornings and cake sales to concerts, barn dances and fashion shows. In the lead up to the challenge and throughout her journey Alison recorded the team's adventure in a blog. Despite never having used social media before, Alison gathered a following of hundreds, creating a real buzz around the event and raising awareness of the cause. *"It took me out of my comfort zone but was great fun. The team contributed their own perspectives and stories to the blog and it's a wonderful record of our team challenge from concept to completion."*

Alison Anderson

"Alison is an inspiration. She is an adventurer in the way she designed and undertook The Cyclopath's challenge whilst raising such significant funds for CPT, but she is also a phenomenal advocate for Parkinson's research, informed and insightful. She is a mentor to others with Parkinson's and is greatly respected and admired for her empathy, knowledge and encouragement."

Helen Matthews, Deputy CEO of The Cure Parkinson's Trust

Vicki Dillon

A special commendation goes to Vicki Dillon who, after being diagnosed with Parkinson's at 35, has dedicated herself to speaking openly about Parkinson's and raising awareness while going that extra mile to help others.

To read more about Vicki and the other wonderful runners-up, please visit **www.cureparkinsons.org.uk/af-2017-runners-up**

Take part... *for a cure*

Join Team CPT at this year's Royal Parks Foundation Half Marathon, taking place on Sunday 14 October 2018. The 13.1 mile route takes runners past some of the capital's world famous landmarks on closed roads as well as through four of London's eight beautiful royal parks. The fantastic half marathon has quickly become CPT's biggest challenge event of the year, and we want you to join us!

If you don't fancy running but have family, friends or colleagues who are taking part for CPT then why not come and join our cheer team to help support, motivate and cheer them on?

Sign Up

Half Marathon - 13.1 miles
Starting and finishing in the stunning Hyde Park
£20 registration fee
Minimum sponsorhip target of £400 each

www.cureparkinsons.org.uk/royalparkshalf

Join our cheer team!

We'll provide you with all the cheer materials you will need including powerstix to make lots of noise and a CPT t-shirt so that you stand out and really feel part of the team.

www.cureparkinsons.org.uk/royalparkshalf

Running Events

Tough Mudder
Various dates from May - September 2018

Scottish Half and 10K
23 September 2018

London Marathon 2019
21 April 2019

Cycling Events

Prudential Ride London 46 and 100
29 July 2018

Tour de Pirineux
26 - 30 September 2018

Trekking Events

Climb Ben Nevis
Various dates in June and August 2018

Yorkshire Three Peaks Challenge
Various dates in July and August 2018

Jurassic Coast Weekend
7 September 2018

To sign up for a challenge please contact George at **george@cureparkinsons.org.uk** or call 020 7487 3892

Attend an event... *for a cure*

Every year The Cure Parkinson's Trust hosts a variety of wonderful events from open gardens to business networking luncheons and this year is no different. Below is a selection of some of the exciting events we have planned for 2018 which we'd love to invite you to. Please visit our website for a full listing of events along with information on how to book your place.

Grouse & Grape Luncheon

9 October 2018
Spencer House, London
www.cureparkinsons.org.uk/grouseandgrape

The 30th Gulls' Eggs Luncheon

15 May 2018
Merchant Taylors' Hall, London
www.cureparkinsons.org.uk/gullseggs

Susie Pasley-Tyler's Gardening Talk

22 June 2018
Preston Capes, Northamptonshire
www.cureparkinsons.org.uk/susiepasleytyler

The Tom Isaacs Charity Golf Day

18 October 2018
Denham Golf Club, Buckinghamshire
www.cureparkinsons.org.uk/denham

Petersham Lodge Open Gardens

20 May 2018
Richmond, Surrey
www.cureparkinsons.org.uk/opengarden

Classic Cars Exhibition

14 July 2018
Guildford
www.cureparkinsons.org.uk/classiccars

Cure^3 Exhibition

25th - 28 October 2018
Bonhams, London
www.cure3.co.uk

Leave a legacy... *for a cure*

Leaving a gift in your will could help future generations. By funding cutting edge research into treatments that have real potential to **slow**, **stop** or even **reverse** the progression of Parkinson's. Andrew Tyrrell was diagnosed with Parkinson's 10 years ago. He is a long-term supporter of The Cure Parkinson's Trust (CPT) and would like to share his experience of leaving a gift to CPT.

"A cure for Parkinson's cannot come soon enough – I want my legacy to be a world without Parkinson's."

"I first encountered CPT just before the 2010 World Parkinson Congress in Glasgow. The charity's energy and determination to find a cure for this condition was infectious. Since then I have supported the charity in numerous ways. I have taken part in focus groups to guide and shape research, I have attended research events on behalf of the charity and fundraised in numerous ways by accepting donations from our weekly 'ManFit' classes to selling raffle tickets at the annual Gulls' Eggs Luncheon.

Following my mother's death, my sister and I inherited a legacy in her will. My mother never knew about my Parkinson's diagnosis, but had she known, I am certain she would have wanted to play a part in delivering a cure for this dreadful condition. When my mother died, my sister and I agreed to make a donation in her name and contribute to some of the exciting and ground-breaking research being funded by CPT towards finding a cure."

Andrew Tyrrell
CPT supporter and Parkinson's Advocate

A legacy need not be in the form of money. Stocks and shares, works of art or other assets such as property are all of significant value to us. Whichever way you may choose to leave us a gift, you have our assurance that you are making a significant difference to the future of those living with Parkinson's.

If you have already made a provision in your will please let CPT know. By telling us your intentions you are not placed under any obligation and can change your mind at any time. It simply enables us to thank you and keep you updated with the latest research news. All legacy information provided to CPT is kept in strictest confidence.

Find out more

If you are interested in leaving a legacy to The Cure Parkinson's Trust our website provides more information about the different options available to you. Please visit, **www.cureparkinsons.org.uk/leave-a-legacy**

Inheritance tax

Leaving at least 10% of the 'net value' of your estate to charity can cut the inheritance Tax (IHT) rate of your estate from 40% to 36%. To find out more please visit, **www.cureparkinsons.org.uk/inheritance-tax**

Farewill - free will writing service

CPT have partnered with Farewill, an online will service, to provide a quick way to make a will free of charge. For more information please visit **www.farewill.com** using the code 'CureParkinsons1' for your 100% discount (RRP £90).

For further information on legacies please contact Theresa at **theresa@cureparkinsons.org.uk** or call 020 7487 3892

Funding... *for a cure*

2017 was our most successful fundraising year to date, with total income of £2.67 million. Most areas of funding support grew in 2017, with a particular boost to our event income and corporate, trust and foundation income. Of this, £2.07 million was directed to our charitable activities, principally funding research to find a cure.

Research expenditure for 2017 was committed to five projects connected with our Linked Clinical Trials programme and six projects involving pre-clinical research.

This means that 78p in every £1 spent in 2017 was directed to charitable activities, with the remainder required for (1) our governance and support costs, and (2) our fundraising costs. We are pleased that this percentage (78%) is so high in 2017, not least as it exceeds our own 5-year average (76%). We will work hard to keep the percentage high in 2018, with good governance, careful cost control and informed investment into the most promising research.

> *"I came across The Cure Parkinson's Trust through my Neurologist. I did some research on the charity and, in addition to the invaluable research they are funding, I was struck by how professionally the charity was run. From the informative website, to the very caring and polished correspondence. Since starting to donate to the charity, I have attended a number of functions they put on for people with Parkinson's, carers, supporters and professionals. The same degree of professionalism was apparent in those functions too and makes CPT my Charity of choice."*

Ian
CPT supporter

Where did our funding support come from?



Where did we spend the funds?



Total Income: £2.67million

Total Expenditure: £2.65 million

Total spend on charitable activities: £2.07 million

78p in every £1 is directed to CPT's charitable activities

Our audited accounts are available at **www.charitycommission.gov.uk** or directly from The Cure Parkinson's Trust by emailing **cptinfo@cureparkinsons.org.uk**

The team... *for a cure*

The Executive Team

William Cook
Chief Executive
will@cureparkinsons.org.uk

Helen Matthews
Deputy Chief Executive
helen@cureparkinsons.org.uk

David Gwynne-Evans
Finance Director
david@cureparkinsons.org.uk

Marketing & Communications

Caroline Morrow
Marketing & Comms Manager
caroline@cureparkinsons.org.uk

Suzanne Bailey
Website & Social Media Editor
suzanne@cureparkinsons.org.uk

Gemma Marks
Marketing Assistant
gemma@cureparkinsons.org.uk

Rachel Cunniffe
Press Officer
rachel@cureparkinsons.org.uk

Fundraising

Anna MacLeod
Fundraising Manager
anna@cureparkinsons.org.uk

Maisie Johnson
Trusts & Corporate Officer
maisie@cureparkinsons.org.uk

Sarah Gibling
Fundraising & Events Coordinator
sarah@cureparkinsons.org.uk

Theresa Samworth
Philanthropy Manager
theresa@cureparkinsons.org.uk

Ella Rogers
Major Gifts Fundraiser
ella@cureparkinsons.org.uk

George Lee
Events & Community
Fundraising Officer
george@cureparkinsons.org.uk

Research & Engagement

Dr Richard Wyse
Director of Research & Development
richard@cureparkinsons.org.uk

Dr Joy Duffen
Special Projects Manager
joy@cureparkinsons.org.uk

Leah Mursaleen
Involvement & Research Officer
leah@cureparkinsons.org.uk

Parkinson's Movement

Julia Jockelson
Website Facilitator & Involvement Officer
julia@cureparkinsons.org.uk

Angie Kehagia
Science Advisor & Research Writer
angie. kehagia@parkinsonsmovement.com

Administration

Jo Malcher
Executive PA & Office Manager
jo@cureparkinsons.org.uk

Trustees:

Connect with Us

@cureparkinsonsT
@cureparkinsons
@cureparkinsonstrust
The Cure Parkinson's Trust

Contact Us

T: + 44 (0)20 7487 3892
E: cptinfo@cureparkinsons.org.uk

The Cure Parkinson's Trust
120 Baker Street
London W1U 6TU

Staying in touch

The General Data Protection Regulation or GDPR comes into force on 25th May 2018. It is a really positive step towards you having more control over how your data is used and how you are contacted. To update your preferences on how you would like to hear from us, please go to **www.cureparkinsons.org.uk/forms/permissions**

The Cure Parkinson's Trust is proud to be a member of the following organisations

amrc
ASSOCIATION OF MEDICAL RESEARCH CHARITIES

Registered with
FUNDRAISING
REGULATOR

The Cure Parkinson's Trust would like to thank **all** the individuals and organisations that have supported us in 2017. Thank you to our patrons, supporters, researchers, scientists, healthcare professionals, collaborators, regular givers, trusts, foundations, corporate supporters, corporate donors, individual fundraisers, key supporters, Parkinson's advocates, committees, members of Parkinson's Movement and our staff and volunteers...

We can't do it without you!

The
Cure
Parkinson's
Trust

www.cureparkinsons.org.uk

Registered with
FUNDRAISING
REGULATOR

The Cure Parkinson's Trust is a registered charity in England and Wales (1111816) and Scotland (SCO44368) and a company limited by guarantee - company number 5539974

amrc
ASSOCIATION OF MEDICAL RESEARCH CHARITIES